The Oncology Institute, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 85.79 million compared to USD 71.42 million a year ago. Net loss was USD 18.75 million compared to USD 11.01 million a year ago. Basic loss per share from continuing operations was USD 0.21 compared to USD 0.12 a year ago. Diluted loss per share from continuing operations was USD 0.21 compared to USD 0.16 a year ago.
For the full year, revenue was USD 324.24 million compared to USD 252.48 million a year ago. Net loss was USD 83.07 million compared to net income of USD 0.152 million a year ago. Basic loss per share from continuing operations was USD 0.92. Diluted loss per share from continuing operations was USD 0.92 compared to USD 0.21 a year ago.